Pacira BioSciences (PCRX) just signed a new partnership with Italy based Molteni Farmaceutici that grants Molteni exclusive rights to distribute Pacira's non opioid postsurgical pain drug EXPAREL across several European countries.
That agreement lands at an interesting moment for Pacira BioSciences. The share price has slipped over the past month, with a 30 day share price return of 4.93% down. Yet year to date the stock is modestly positive, and the 1 year total shareholder return of 4.94% contrasts with a much weaker 3 year and 5 year total shareholder return. This signals that longer term momentum has been softer even as investors reassess the story around moves like the Molteni deal.
Scan beyond Pacira BioSciences and find other pain management and healthcare specialists that screen strongly on balance sheets and fundamentals with our curated list of solid balance sheet and fundamentals (25 results) .
Bulls point to Pacira BioSciences' profit growth, new European EXPAREL royalties and a hefty implied discount to intrinsic value, while bears focus on soft longer term returns and concentration risk. Which case does the current valuation actually support?
Most Popular Narrative: 34% Undervalued
Pacira BioSciences closed at $25.05, while the most followed narrative anchors on a Fair Value estimate of $38. This points to a sizeable gap that bulls tie to patent life, reimbursement and pipeline progress rather than short term sentiment.
Earlier claims around intellectual property protection centred on long dated exclusivity. The shift from a single listed EXPAREL patent to 21 patents, combined with a settlement that limits generic entry until 2039, now adds clearer visibility on high margin EXPAREL cash flow duration. This could support higher long term earnings power than is currently embedded in forecasts.
See why 2 investors see Pacira BioSciences as 34% undervalued .
Result: Fair Value of $38 (UNDERVALUED)
Still, Pacira BioSciences faces real pressure if higher non GAAP R&D spending does not translate into approvals, or if EXPAREL reimbursement or patent protections weaken sooner than expected.
Find out about the key risks to this Pacira BioSciences narrative .
Another View: Pacira BioSciences Looks Expensive On Earnings
There is a big catch to the Pacira BioSciences undervaluation story. On a simple P/E lens, the stock trades at 68.2x compared with 15.3x for the wider US pharmaceuticals group, 9.5x for peers and a fair ratio of 19.8x. That gap points to real valuation risk if sentiment cools.
To see how the numbers stack up when earnings multiples do the heavy lifting rather than cash flow forecasts, See what the numbers say about this price — find out in our valuation breakdown. .
Next Steps
Mixed messages around Pacira BioSciences can make the story feel muddled, so move quickly, review the full data set, and lean on the 3 key rewards and 1 important warning sign .
Looking for more Pacira BioSciences sized opportunities?
If Pacira BioSciences has you rethinking where the next edge might be, do not stop here. Broaden your watchlist now or risk missing the next setup.
-
Target resilient balance sheets and consistent fundamentals by scanning a curated list of solid balance sheet and fundamentals (25 results) that filters for financial strength first.
-
Hunt for quality at a discount by reviewing a focused group of 27 high quality undervalued stocks that may offer more compelling entry points.
-
Prioritise staying power and lower volatility by checking a refined pool of 31 resilient stocks with low risk scores that keep risk management front and centre.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PCRX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
